Synthetic double-stranded RNA induces innate immune responses similar to a live viral vaccine in humans
Marina Caskey, François Lefebvre, Abdelali Filali-Mouhim, Mark J Cameron, Jean-Philippe Goulet, Elias K Haddad, Gaëlle Breton, Christine Trumpfheller, Sarah Pollak, Irina Shimeliovich, Angela Duque-Alarcon, Li Pan, Annette Nelkenbaum, Andres M Salazar, Sarah J Schlesinger, Ralph M Steinman, Rafick P Sékaly, Marina Caskey, François Lefebvre, Abdelali Filali-Mouhim, Mark J Cameron, Jean-Philippe Goulet, Elias K Haddad, Gaëlle Breton, Christine Trumpfheller, Sarah Pollak, Irina Shimeliovich, Angela Duque-Alarcon, Li Pan, Annette Nelkenbaum, Andres M Salazar, Sarah J Schlesinger, Ralph M Steinman, Rafick P Sékaly
Abstract
Adjuvants are critical for the success of vaccines. Agonists of microbial pattern recognition receptors (PRRs) are promising new adjuvant candidates. A mechanism through which adjuvants enhance immune responses is to stimulate innate immunity. We studied the innate immune response in humans to synthetic double-stranded RNA (polyinosinic:polycytidylic acid [poly IC] stabilized with poly-L-lysine [poly ICLC]), an agonist for toll-like receptor (TLR) 3, and the cytosolic RNA helicase MDA-5. Transcriptional analysis of blood samples from eight volunteers, after subcutaneous administration of poly ICLC, showed up-regulation of genes involved in multiple innate immune pathways in all subjects, including interferon (IFN) and inflammasome signaling. Blocking type I IFN receptor ex vivo significantly dampened the response to poly IC. Comparative transcriptional analysis showed that several innate immune pathways were similarly induced in volunteers immunized with the highly efficacious yellow fever vaccine. Therefore, a chemically defined PRR agonist like poly ICLC can be a reliable and authentic microbial mimic for inducing innate immune responses in humans.
Figures
References
- Alexopoulou L., Holt A.C., Medzhitov R., Flavell R.A. 2001. Recognition of double-stranded RNA and activation of NF-kappaB by Toll-like receptor 3. Nature. 413:732–738 10.1038/35099560
- Amit I., Garber M., Chevrier N., Leite A.P., Donner Y., Eisenhaure T., Guttman M., Grenier J.K., Li W., Zuk O., et al. 2009. Unbiased reconstruction of a mammalian transcriptional network mediating pathogen responses. Science. 326:257–263 10.1126/science.1179050
- Benjamini Y., Hochberg Y. 1995. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J. R. Stat. Soc. Series B Stat. Methodol. 57:289–300
- Beutler B. 2004. Inferences, questions and possibilities in Toll-like receptor signalling. Nature. 430:257–263 10.1038/nature02761
- Coffman R.L., Sher A., Seder R.A. 2010. Vaccine adjuvants: putting innate immunity to work. Immunity. 33:492–503 10.1016/j.immuni.2010.10.002
- García M.A., Gil J., Ventoso I., Guerra S., Domingo E., Rivas C., Esteban M. 2006. Impact of protein kinase PKR in cell biology: from antiviral to antiproliferative action. Microbiol. Mol. Biol. Rev. 70:1032–1060 10.1128/MMBR.00027-06
- Gaucher D., Therrien R., Kettaf N., Angermann B.R., Boucher G., Filali-Mouhim A., Moser J.M., Mehta R.S., Drake D.R., III, Castro E., et al. 2008. Yellow fever vaccine induces integrated multilineage and polyfunctional immune responses. J. Exp. Med. 205:3119–3131 10.1084/jem.20082292
- Gentleman R.C., Carey V.J., Bates D.M., Bolstad B., Dettling M., Dudoit S., Ellis B., Gautier L., Ge Y., Gentry J., et al. 2004. Bioconductor: open software development for computational biology and bioinformatics. Genome Biol. 5:R80 10.1186/gb-2004-5-10-r80
- Germain R.N. 2010. Vaccines and the future of human immunology. Immunity. 33:441–450 10.1016/j.immuni.2010.09.014
- Guarda G., So A. 2010. Regulation of inflammasome activity. Immunology. 130:329–336 10.1111/j.1365-2567.2010.03283.x
- Harris J., Sharp F.A., Lavelle E.C. 2010. The role of inflammasomes in the immunostimulatory effects of particulate vaccine adjuvants. Eur. J. Immunol. 40:634–638 10.1002/eji.200940172
- Huang C.C., Duffy K.E., San Mateo L.R., Amegadzie B.Y., Sarisky R.T., Mbow M.L. 2006. A pathway analysis of poly(I:C)-induced global gene expression change in human peripheral blood mononuclear cells. Physiol. Genomics. 26:125–133 10.1152/physiolgenomics.00002.2006
- Ichinohe T., Lee H.K., Ogura Y., Flavell R., Iwasaki A. 2009. Inflammasome recognition of influenza virus is essential for adaptive immune responses. J. Exp. Med. 206:79–87 10.1084/jem.20081667
- Johnson W.E., Li C., Rabinovic A. 2007. Adjusting batch effects in microarray expression data using empirical Bayes methods. Biostatistics. 8:118–127 10.1093/biostatistics/kxj037
- Kawai T., Akira S. 2010. The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors. Nat. Immunol. 11:373–384 10.1038/ni.1863
- Kolumam G.A., Thomas S., Thompson L.J., Sprent J., Murali-Krishna K. 2005. Type I interferons act directly on CD8 T cells to allow clonal expansion and memory formation in response to viral infection. J. Exp. Med. 202:637–650 10.1084/jem.20050821
- Lamkanfi M., Dixit V.M. 2009. Inflammasomes: guardians of cytosolic sanctity. Immunol. Rev. 227:95–105 10.1111/j.1600-065X.2008.00730.x
- Le Bon A., Schiavoni G., D’Agostino G., Gresser I., Belardelli F., Tough D.F. 2001. Type i interferons potently enhance humoral immunity and can promote isotype switching by stimulating dendritic cells in vivo. Immunity. 14:461–470 10.1016/S1074-7613(01)00126-1
- Le Bon A., Durand V., Kamphuis E., Thompson C., Bulfone-Paus S., Rossmann C., Kalinke U., Tough D.F. 2006. Direct stimulation of T cells by type I IFN enhances the CD8+ T cell response during cross-priming. J. Immunol. 176:4682–4689
- Longhi M.P., Trumpfheller C., Idoyaga J., Caskey M., Matos I., Kluger C., Salazar A.M., Colonna M., Steinman R.M. 2009. Dendritic cells require a systemic type I interferon response to mature and induce CD4+ Th1 immunity with poly IC as adjuvant. J. Exp. Med. 206:1589–1602 10.1084/jem.20090247
- Meylan E., Tschopp J. 2006. Toll-like receptors and RNA helicases: two parallel ways to trigger antiviral responses. Mol. Cell. 22:561–569 10.1016/j.molcel.2006.05.012
- Morse M.A., Chapman R., Powderly J., Blackwell K.L., Keler T., Green J., Riggs R., He L.Z., Ramakrishna V., Vitale L., et al. 2011. Phase I study utilizing a novel antigen-presenting cell-targeted vaccine with Toll-like receptor stimulation to induce immunity to self-antigens in cancer patients. Clin. Cancer Res. 17:4844–4853 10.1158/1078-0432.CCR-11-0891
- Okada H., Kalinski P., Ueda R., Hoji A., Kohanbash G., Donegan T.E., Mintz A.H., Engh J.A., Bartlett D.L., Brown C.K., et al. 2011. Induction of CD8+ T-cell responses against novel glioma-associated antigen peptides and clinical activity by vaccinations with alpha-type 1 polarized dendritic cells and polyinosinic-polycytidylic acid stabilized by lysine and carboxymethylcellulose in patients with recurrent malignant glioma. J. Clin. Oncol. 29:330–336 10.1200/JCO.2010.30.7744
- Plotkin S.A. 2008. Vaccines: correlates of vaccine-induced immunity. Clin. Infect. Dis. 47:401–409 10.1086/589862
- Pulendran B., Ahmed R. 2006. Translating innate immunity into immunological memory: implications for vaccine development. Cell. 124:849–863 10.1016/j.cell.2006.02.019
- Querec T., Bennouna S., Alkan S., Laouar Y., Gorden K., Flavell R., Akira S., Ahmed R., Pulendran B. 2006. Yellow fever vaccine YF-17D activates multiple dendritic cell subsets via TLR2, 7, 8, and 9 to stimulate polyvalent immunity. J. Exp. Med. 203:413–424 10.1084/jem.20051720
- Querec T.D., Akondy R.S., Lee E.K., Cao W., Nakaya H.I., Teuwen D., Pirani A., Gernert K., Deng J., Marzolf B., et al. 2009. Systems biology approach predicts immunogenicity of the yellow fever vaccine in humans. Nat. Immunol. 10:116–125 10.1038/ni.1688
- Reed S.G., Bertholet S., Coler R.N., Friede M. 2009. New horizons in adjuvants for vaccine development. Trends Immunol. 30:23–32 10.1016/j.it.2008.09.006
- Rosenfeld M.R., Chamberlain M.C., Grossman S.A., Peereboom D.M., Lesser G.J., Batchelor T.T., Desideri S., Salazar A.M., Ye X. 2010. A multi-institution phase II study of poly-ICLC and radiotherapy with concurrent and adjuvant temozolomide in adults with newly diagnosed glioblastoma. Neuro-oncol. 12:1071–1077 10.1093/neuonc/noq071
- Schoggins J.W., Wilson S.J., Panis M., Murphy M.Y., Jones C.T., Bieniasz P., Rice C.M. 2011. A diverse range of gene products are effectors of the type I interferon antiviral response. Nature. 472:481–485 10.1038/nature09907
- Smyth G.K. 2004. Linear models and empirical bayes methods for assessing differential expression in microarray experiments. Stat. Appl. Genet. Mol. Biol. 3:e3
- Stahl-Hennig C., Eisenblätter M., Jasny E., Rzehak T., Tenner-Racz K., Trumpfheller C., Salazar A.M., Uberla K., Nieto K., Kleinschmidt J., et al. 2009. Synthetic double-stranded RNAs are adjuvants for the induction of T helper 1 and humoral immune responses to human papillomavirus in rhesus macaques. PLoS Pathog. 5:e1000373 10.1371/journal.ppat.1000373
- Waddell S.J., Popper S.J., Rubins K.H., Griffiths M.J., Brown P.O., Levin M., Relman D.A. 2010. Dissecting interferon-induced transcriptional programs in human peripheral blood cells. PLoS ONE. 5:e9753 10.1371/journal.pone.0009753
- Xu W., Santini P.A., Matthews A.J., Chiu A., Plebani A., He B., Chen K., Cerutti A. 2008. Viral double-stranded RNA triggers Ig class switching by activating upper respiratory mucosa B cells through an innate TLR3 pathway involving BAFF. J. Immunol. 181:276–287
Source: PubMed